2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 306

Investigating the Pathogenic Role of ER Stress Pathways in the Idiopathic Inflammatory Myopathies (IIM): Interrogating the Role of Micro-RNA 133a As an Important Regulator of ER Stress Activation
Abstract Number: 307

Screening for Pulmonary Hypertension in the Anti-Synthetase Syndrome; Utility of Four Different Screening Approaches
Abstract Number: 308

Nailfold Capillaroscopy in Patients with Early Onset-Dermatomyositis
Abstract Number: 309

Plasma Levels of Heat Shock Protein 90 Are Increased in Idiopathic Inflammatory Myopathies and Correlate with Disease Activity, Skeletal Muscle, Heart and Lung Involvement
Abstract Number: 310

Hyaluronic Acid Injections in Knee Osteoarthritis Patients Are Associated with Delay to Knee Arthroplasty
Abstract Number: 311

Comparison Between Intra Articular Ozone and Placebo in the Treatment of Knee Osteoarthritis: A Multicentric, Comparative, Randomized and Double-Blinded Clinical Trial
Abstract Number: 312

Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Abstract Number: 313

Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study
Abstract Number: 314

A Double-Blind, Randomized, Controlled, Four Parallel Arm, Dose-Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Intra-Articular (IA) Injections of Fasitibant in Patients with Symptomatic OA of the Knee
Abstract Number: 315

Structural Effects of Sprifermin in Knee Osteoarthritis: A Post-Hoc Analysis on Cartilage and Non-Cartilaginous Tissue Alterations
Abstract Number: 316

Effect of Vitamin D on Effusion-Synovitis in Knee Osteoarthritis: a Randomized Controlled Trial
Abstract Number: 317

Relation of Incident Bisphosphonate Use to Trajectory of Joint-Space Width
Abstract Number: 318

Dual Variable Domain-Immunoglobulin (Dvd-Igâ„¢) Abt-981 Simultaneously and Dose-Dependently Inhibits Interleukin-1 Î‘lpha and -1 Î’eta in Subjects with Knee Osteoarthritis
Abstract Number: 319

Phase 1 Studies of Anti-Interleukin-1 Dual-Variable Domain Immunoglobulin in Healthy Subjects and Patients with Osteoarthritis
Abstract Number: 320

Effectiveness of Bracing in Elderly with Knee Osteoartritis: A Randomized Controlled Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].